Key takeaway
What This Development Means
From 1 January 2026, the European Pharmacopoeia will eliminate animal-based pyrogen testing, mandating synthetic alternatives such as recombinant Factor C. This change will enhance scientific consistency, reduce environmental impact, and align with ethical standards across the pharmaceutical and chemicals sectors.
What is replacing the rabbit pyrogen test in the European Pharmacopoeia?
The rabbit pyrogen test will be replaced by a range of validated, animal-free methods. These include recombinant Factor C (rFC) and the monocyte activation test (MAT), selected based on risk assessment and the specific characteristics of the tested substance.
How will this change affect pharmaceutical manufacturers?
Manufacturers must update their testing protocols to adopt approved animal-free alternatives. This may require validating new methods, training staff, and aligning with updated regulatory documentation to ensure compliance with Ph. Eur. from 2026 onward.
Source basis: A major step towards animal-free testing for the test for bacterial endotoxins
A major shift in European chemical and pharmaceutical testing regulations is set to take effect from 1 January 2026, as the European Pharmacopoeia (Ph. Eur.) eliminates the use of the rabbit pyrogen test (RPT). This milestone marks a decisive move towards animal-free testing for bacterial endotoxins and aligns with evolving ethical and scientific standards across the chemicals and biopharmaceutical sectors. Under the new approach, manufacturers must transition to modern, validated alternatives, such as recombinant Factor C (rFC) and the monocyte activation test (MAT).
These methods are not only animal-free but also offer increased consistency and scientific rigour.
Shift Away From Rabbit-Based Testing
The withdrawal of general chapter 2.6.8 (Pyrogens) from Ph.
Eur. texts signals the end of a decades-long reliance on the RPT, which traditionally used rabbits to detect fever-inducing contaminants in pharmaceutical products.
From 2026, pyrogen testing will be governed by general chapter 2.6.30, which outlines a risk-based selection of suitable non-endotoxin pyrogen tests. Meanwhile, general chapter 5.1.13 (Pyrogenicity) places the responsibility on users to choose an appropriate method based on the product profile and scientific justification. The EPC (European Pharmacopoeia Commission) has officially endorsed recombinant Factor C as one of seven approved endotoxin detection methods, positioning it as a validated synthetic alternative that avoids the use of horseshoe crab blood.
Broader Industry Implications
This regulatory change has significant implications for pharmaceutical and biopharmaceutical manufacturers, contract laboratories, and suppliers of endotoxin detection reagents. Beyond animal welfare, the move addresses growing concerns around the sustainability of horseshoe crab populations and the variability of biological reagents. The EDQM (European Directorate for the Quality of Medicines & HealthCare) and the European Partnership for Alternative Approaches to Animal Testing (EPAA) are coordinating stakeholder engagement through a joint symposium scheduled for 25–26 February 2026 in Brussels.
The event will highlight regulatory expectations, practical implementation strategies, and innovation in pyrogen testing technologies.
A Step Towards Global Harmonisation
While recombinant Cascade Reagents (rCR) are not yet included in the Ph. Eur., the EPC is encouraging data submission to support their potential adoption. This forward-looking approach reflects the broader aim of achieving global harmonisation in testing standards and fostering cross-border pharmaceutical innovation. The phase-out strategy is aligned with Directive 2010/63/EU on animal welfare and underscores the EU’s commitment to 3Rs (Replacement, Reduction, and Refinement) principles in scientific testing.
Related Articles
European Parliament Backs Expanded Powers For European Chemicals Agency
The European Parliament’s proposed reforms would substantially expand ECHA’s scientific, regulatory and coordination functions. The changes reinforce transparency, non-animal testing and inter-agency cooperation while increasing regulatory oversight across the EU chemicals sector.
EFSA Seeks Feedback On Overhaul Of Weight Of Evidence And Biological Relevance Guidance
EFSA launches consultation on updating its Weight of Evidence and Biological Relevance guidance, aiming to streamline chemical risk assessment practices.
New Guidance Released For Minimising Animal Testing Under UK REACH
The HSE's latest guidance under UK REACH outlines steps to minimise animal testing by adopting in vitro, in silico, and other alternative approaches.
